首页 > 资讯 > 资讯公开 > OpenFDA—创新的FDA公开数据搜索和分析解决方案

出自识林

2014-06-05 FDA

FDA推出openFDA提供获取FDA重要公开数据的简易途径

6月2日FDA推出openFDA，这项新的举措用于为web开发人员、研究人员和公众访问FDA收集的庞大的、重要的公共卫生数据集提供方便的访问。

为配合近期关于开放数据的总统行政令和卫生与人类服务部卫生数据的动议，openFDA将使FDA的公开数据以结构化的、计算机可读的格式获取，这将使技术专家（例如移动应用程序开发人员、web开发人员、数据可视化艺术家和研究人员）可以快速搜索、查询或根据需要即刻直接从FDA数据库拉取公开信息的海量数据。

OpenFDA采用基于搜索的应用程序接口收集大量现有的公开数据，为开发人员提供通过文本搜索数据的功能，并对搜索结果像使用Google一样排序。这种方式可以让开发者在openFDA之上构建自己的应用程序，给开发者大量的灵活性来决定他们希望搜索什么类型的数据，以及希望如何向最终用户呈现这些数据。这使得将各种应用程序构建在一个共同的平台之上成为可能。

FDA首席运营官和代理首席信息官Walter S. Harris指出，“openFDA主动利用新的技术和方法解锁巨大的公众数据和资源，使得这些资源可以从FDA以一种用户友好的方式获得”。“openFDA是一个宝贵的资源，这将帮助那些私营和公共部门使用FDA公开数据激励创新、推动学术研究、教育公正并保护公众健康。”

该提议是与内部职员和外部开发人员广泛研究以确定这些数据集是经常性的需求且传统上相当难使用的结果。根据这一研究，FDA决定逐步引入openFDA，以2004到2013年提交给FDA的涉及数百万药物不良事件和用药错误报告的初始试点项目作为开始。过去，数据仅能通过很难使用的报告或信息自由法案请求获取。

这一举措中提供的不良事件数据不包含任何可能被用来识别个人或其他私人信息的数据。该试点稍后将被扩大至包含FDA产品召回和产品标签数据库。

FDA首席医疗信息官Taha Kass医学博士指出，“通过这一新颖的和与众不同的方法来组织数据，使得这些报告可全部获取，从而使软件开发人员可以构建工具帮助预示潜在安全信息，得出重要的见解并帮助消费者和医疗保健专业人士及时获得信息”。“openFDA提供了一个可扩展的平台，可以轻松地跨多个不同的数据集搜索和查询，而且可以很容易地重新部署或改变以适应各种用途。openFDA提供了一个创新的公开数据搜索和分析解决方案。”

除了提供数据集，openFDA将鼓励通过强调潜在数据应用并提供社区互动以及与FDA领域专家的互动空间来鼓励对FDA公开数据的创新性使用。

FDA将继续努力以确定额外的公开数据集供openFDA使用。更多信息请查看open.FDA.gov，您也可以发送电子邮件到open@fda.hhs.gov获取更多信息。

openFDA倡议由FDA首席医疗信息官(Chief Health Informatics Officer, CHIO)和信息与技术创新办公室(Office of Informatics and Technology Innovation, OITI)正式创立和推出。

编译：识林-椒 2014-06-05

FDA launches openFDA to provide easy access to valuable FDA public data
For Immediate Release: June 2, 2014

Today, the U.S. Food and Drug Administration launched openFDA, a new initiative designed to make it easier for web developers, researchers, and the public to access large, important public health datasets collected by the agency.

In alignment with the recent Presidential Executive Order on Open Data and the Department of Health and Human Services Health Data Initiative, openFDA will make the FDA’s publicly available data accessible in a structured, computer readable format that will make it possible for technology specialists, such as mobile application creators, web developers, data visualization artists and researchers to quickly search, query, or pull massive amounts of public information instantaneously and directly from FDA datasets on an as needed basis.

OpenFDA utilizes a search-based Application Program Interface (API) to collect large amounts of existing publicly available data, offering developers the ability to search through text within that data, ranking results much like a search using Google would do. This method then allows them to build their own applications on top of openFDA, giving them a large amount of flexibility to determine what types of data they would like to search and how they would like to present that data to end-users. This enables a wide variety of applications to be built on one common platform.

“The openFDA initiative leverages new technologies and methods to unlock the tremendous public data and resources available from the FDA in a user-friendly way,” said Walter S. Harris, the FDA’s chief operating officer and acting chief information officer. “OpenFDA is a valuable resource that will help those in the private and public sectors use FDA public data to spur innovation, advance academic research, educate the public, and protect public health.”

The initiative is the result of extensive research with internal officials and external developers to identify those datasets that are in recurrent demand and are traditionally fairly difficult to use. Based on this research, the FDA decided to phase in openFDA beginning with an initial pilot program involving the millions of reports of drug adverse events and medication errors that have been submitted to the FDA from 2004 to 2013. Previously, the data was only available through difficult to use reports or Freedom of Information Act requests.

The adverse events data made available under this initiative do not contain any data that could potentially be used to identify individuals or other private information. The pilot will later be expanded to include the FDA’s databases on product recalls and product labeling.

“Through this new and novel approach to data organization, these reports will be available in their entirety so that software developers can build tools to help signal potential safety information, derive meaningful insights, and get information to consumers and health care professionals in a timely manner,” said Taha Kass-Hout, M.D., the FDA’s chief health informatics officer. “OpenFDA offers a scalable platform that can be easily searched and queried across many distinct datasets, and can be easily redeployed or altered to fit a variety of purposes, and provides an innovative public data search and analytics solution.”

In addition to providing datasets, openFDA will encourage the innovative use of the agency’s publicly available data by highlighting potential data applications and providing, a place for community interaction with each other and with FDA domain experts.

The FDA will continually work to identify additional public datasets to make available through openFDA. More information can be found at open.FDA.gov or you can email the FDA for more information at open@fda.hhs.gov.

The openFDA Initiative was formally launched with the creation of the Chief Health Informatics Officer (CHIO) and the Office of Informatics and Technology Innovation (OITI) at the FDA.

识林www.shilinx.com，版权所有，如需转载请注明出处